Streaming Delayed Price  /  Updated: 8:10 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
() Community Analysis from
April 20, 2014
(Stock Blog Hub, 5/15/13)
Aegerion Pharmaceuticals, Inc. (AEGR) reported first quarter 2013 net loss per share of 64 cents, narrower than the Zacks Consensus Estimate of a loss of 72 cents, but...(read more)
(Stock Blog Hub, 1/16/13)
Aegerion Pharmaceuticals, Inc. (AEGR) recently provided more details on its public offering. The offering is expected to close on Jan 16, 2013. The total offer consists of...(read more)
(Penny Stock DD, 3/17/11)
Aegerion Pharmaceuticals has received federal orphan drug status for its lead candidate, a treatment for people with severe lipid disorders. Orphan drug status is given to drugs that...(read more)
Aegerion Pharmaceuticals (AEGR) Company Overview

There is no analysis for yet. But you can go to Wikinvest to help create one!

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here